Biopharma company CSL Behring is investing 610 million euros to expand its Marburg production site, creating at least 100 new jobs by 2030.
The capital injection aims to boost manufacturing capacity for plasma-based therapies intended for patients with rare, chronic, and severe medical conditions. Company representatives said that the funding secures existing regional employment while expanding the workforce by roughly 100 positions.
“Die Investition unterstreiche das langfristige Engagement für Marburg, für Deutschland und vor allem für die Patientinnen und Patienten,” erklärte Annegret Wittich-Hoeffer, Leiterin des CSL-Geschäfts in der Region Deutschland, Österreich und der Schweiz. She added that employees in Marburg manufacture medicines distributed to more than 100 countries, making the site essential for European health security and sovereignty.
The investment follows recent restructuring at the facility, where the German subsidiary previously halted research and development activities and announced cuts totaling roughly 780 jobs. Despite those reductions, executives previously confirmed that Marburg remains a cornerstone production hub within the global network.
Funding finances new filling lines and bulk facility
The funding package finances two new filling lines equipped with eight freeze-dryers dedicated to plasma-based therapies, with operations slated to begin by 2029. Funds will also construct a new bulk facility for fibrinogen, a medication used to treat life-threatening bleeding and coagulation disorders resulting from trauma or surgeries.
A portion of the budget goes toward modernizing existing machinery, automation, and digital process control systems. Company officials noted these upgrades increase long-term production resilience and help retain critical manufacturing know-how within Germany.
Growing global demand for plasma therapies
More than 300,000 patients across Europe rely on plasma-based therapies, and worldwide demand continues to rise. The Marburg facility currently employs more than 2,800 workers, producing approximately 18 million packaged medicine units during the 2025/2026 financial year ending June 30.
CSL Behring operates as a subsidiary of the Australian corporation CSL, headquartered in Melbourne. The parent company employs 29,000 people globally across four manufacturing plants, with Marburg serving as the largest production site in the corporate network.
| Facility Metric | Figure |
|---|---|
| Investment Sum | 610 million euros |
| New Jobs Created | At least 100 |
| Current Workforce | More than 2,800 |
| Annual Production Volume | ~18 million medicine units |
Political reception in Hesse
Company leaders unveiled the expansion during an event attended by roughly 100 invited guests, including Kaweh Mansoori, parliamentary state secretary Georg Kippels, and Martin Blessing, personal special representative of the German Chancellor for investments.

Blessing described the decision as a vote of confidence in Germany as an industrial base, noting that international capital weighs investment destinations carefully. “Wir können also nur gewinnen, wenn wir produktiver, innovativer und schneller sind,” Blessing told Hessenschau.de, emphasizing the need to improve regulatory frameworks and curb labor ancillary costs.
Marburg Lord Thomas Spies welcomed the announcement, calling it a day to celebrate and a clear commitment to the municipality as an attractive business location.
Frequently asked questions about the Marburg expansion
When are the new filling lines scheduled to begin operations?
The two new filling lines and eight freeze-dryers are scheduled to launch operations by 2029.
What medical condition does fibrinogen treat?
Fibrinogen treats life-threatening bleeding and coagulation disorders that can arise from trauma or surgical procedures.
CSL Behring traces its roots to 1904, when Emil von Behring, the first Nobel laureate in Medicine, founded Behringwerke in Marburg to develop sera and vaccines.
The modern company emerged from the 2007 rebranding of ZLB Behring after CSL Limited, Australia’s Commonwealth Serum Laboratories established in 1916, acquired the German business and combined it with Aventis Behring in 2004. Today the subsidiary operates CSL Plasma, with more than 270 collection centres across the United States, Europe and China.
How many countries receive medicines produced at the Marburg site?
Employees in Marburg manufacture pharmaceutical products distributed to more than 100 countries worldwide.